According to a recent LinkedIn post from FluoretiQ Limited, the veterinary point-of-care diagnostics market is projected to reach $7.2 billion by 2035, growing at a 9.2% compound annual rate. The post attributes this outlook to a shift in veterinary practice, with clinicians and pet owners increasingly expecting rapid, in-clinic test results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights rapid in-clinic testing as the fastest-growing segment within this market, emphasizing its relevance to routine veterinary workflows. FluoretiQ’s Veri-5 Vet product is portrayed as targeting this segment by providing UTI pathogen identification in 15 minutes, within the consultation window.
For investors, the post suggests that FluoretiQ is positioning itself to capture a share of a growing niche in veterinary diagnostics, where time-to-result is a key differentiator. If the product gains clinical adoption and proves cost-effective for practices, this could support revenue growth and strengthen the company’s competitive positioning in animal health diagnostics.
The reference to third-party market research from Precedence Research indicates that FluoretiQ is aligning its strategy with broader industry growth forecasts. However, the post does not provide details on pricing, regulatory status, distribution, or adoption metrics, which remain important factors for assessing the company’s long-term financial impact and execution risk.